mAb-话题@MedSci

#mAb#

1302篇内容 | 2879人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912341, encodeId=b376191234129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用, objectType=article, longId=193027, objectId=5ab819302e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ab819302e68, replyNumber=0, likeNumber=62, createdTime=2021-01-29, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ab819302e68, moduleTitle=全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ab819302e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912467, encodeId=b813191246eae, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ACG 2020：相比于英夫利昔单抗，Vedolizumab显著改善与免疫治疗有关的腹泻, objectType=article, longId=202652, objectId=2f2020265283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f2020265283, replyNumber=0, likeNumber=62, createdTime=2021-06-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f2020265283, moduleTitle=ACG 2020：相比于英夫利昔单抗，Vedolizumab显著改善与免疫治疗有关的腹泻, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f2020265283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912551, encodeId=1566191255159, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Emgality（galcanezumab）治疗阵发性丛集性头痛：已在加拿大获得批准, objectType=article, longId=207661, objectId=8a1820e661cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1820e661cb, replyNumber=0, likeNumber=0, createdTime=2021-06-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1820e661cb, moduleTitle=Emgality（galcanezumab）治疗阵发性丛集性头痛：已在加拿大获得批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1820e661cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912535, encodeId=63bc19125354f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据, objectType=article, longId=206929, objectId=119120692979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=119120692979, replyNumber=0, likeNumber=70, createdTime=2021-02-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=119120692979, moduleTitle=UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=119120692979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912524, encodeId=9cf81912524ce, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量, objectType=article, longId=206250, objectId=56f72062509e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f72062509e, replyNumber=0, likeNumber=95, createdTime=2021-03-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f72062509e, moduleTitle=JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f72062509e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912391, encodeId=b523191239142, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM: Trastuzumab Deruxtecan治疗HER2阳性晚期胃癌II期效果显著, objectType=article, longId=196097, objectId=c0f719609e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f719609e16, replyNumber=0, likeNumber=74, createdTime=2020-12-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f719609e16, moduleTitle=NEJM: Trastuzumab Deruxtecan治疗HER2阳性晚期胃癌II期效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f719609e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912514, encodeId=9b27191251402, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JAMA Netw Open：新型减肥药Bimagrumab 对2型糖尿病和肥胖成人体脂质量的影响, objectType=article, longId=205785, objectId=b28a205e8562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b28a205e8562, replyNumber=0, likeNumber=109, createdTime=2021-04-20, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b28a205e8562, moduleTitle=JAMA Netw Open：新型减肥药Bimagrumab 对2型糖尿病和肥胖成人体脂质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b28a205e8562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912519, encodeId=75441912519fb, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性, objectType=article, longId=205972, objectId=009f2059e2f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=009f2059e2f7, replyNumber=0, likeNumber=67, createdTime=2021-10-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=009f2059e2f7, moduleTitle=ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=009f2059e2f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912463, encodeId=879b1912463f2, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, objectType=article, longId=202384, objectId=f40b202384ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40b202384ce, replyNumber=0, likeNumber=100, createdTime=2021-01-17, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40b202384ce, moduleTitle=CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40b202384ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912423, encodeId=bf261912423c9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, objectType=article, longId=199142, objectId=daaa19914221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=daaa19914221, replyNumber=0, likeNumber=58, createdTime=2021-06-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daaa19914221, moduleTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daaa19914221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912419, encodeId=ba81191241960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=美国国立卫生研究院选择Lenzilumab进行COVID-19的大效应试验（BET）, objectType=article, longId=198194, objectId=3d8e198194c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d8e198194c7, replyNumber=0, likeNumber=75, createdTime=2020-12-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d8e198194c7, moduleTitle=美国国立卫生研究院选择Lenzilumab进行COVID-19的大效应试验（BET）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d8e198194c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912496, encodeId=e7001912496c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, objectType=article, longId=204048, objectId=2fa5204048fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fa5204048fb, replyNumber=0, likeNumber=73, createdTime=2021-03-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fa5204048fb, moduleTitle=Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fa5204048fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912394, encodeId=eabe191239443, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Heart J：Alirocumab 对高龄冠心病患者预后的影响研究, objectType=article, longId=196733, objectId=d89c196e3356, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89c196e3356, replyNumber=0, likeNumber=59, createdTime=2020-09-18, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89c196e3356, moduleTitle=Eur Heart J：Alirocumab 对高龄冠心病患者预后的影响研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89c196e3356)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912465, encodeId=e1d319124652c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Tocilizumab用于新冠肺炎住院患者的治疗, objectType=article, longId=202406, objectId=cb3c20240697, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb3c20240697, replyNumber=0, likeNumber=80, createdTime=2020-11-20, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb3c20240697, moduleTitle=NEJM：Tocilizumab用于新冠肺炎住院患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb3c20240697)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912432, encodeId=6663191243229, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, objectType=article, longId=199783, objectId=eb8f199e83c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb8f199e83c9, replyNumber=0, likeNumber=0, createdTime=2021-03-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb8f199e83c9, moduleTitle=FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb8f199e83c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912509, encodeId=877a1912509ff, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格” , objectType=article, longId=205518, objectId=dfc82055184d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc82055184d, replyNumber=0, likeNumber=77, createdTime=2021-11-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc82055184d, moduleTitle=FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格” , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc82055184d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912417, encodeId=91ab191241e4b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=71, createdTime=2021-05-05, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912368, encodeId=1dc51912368b7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JACC：Evolocumab对血脂异常HIV携带者的疗效研究, objectType=article, longId=194710, objectId=89a3194e1091, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89a3194e1091, replyNumber=0, likeNumber=81, createdTime=2020-11-20, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89a3194e1091, moduleTitle=JACC：Evolocumab对血脂异常HIV携带者的疗效研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89a3194e1091)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912373, encodeId=27ef19123e3a8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=65, createdTime=2021-02-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912387, encodeId=e5ee191238e3b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著, objectType=article, longId=195876, objectId=4d741958e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d741958e69f, replyNumber=0, likeNumber=76, createdTime=2020-09-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d741958e69f, moduleTitle=SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d741958e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

全新分析支持PD-1抑制剂dostarlimab在子宫内膜癌中的应用

2021-01-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ACG 2020：相比于英夫利昔单抗，Vedolizumab显著改善与免疫治疗有关的腹泻

2021-06-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Emgality（galcanezumab）治疗阵发性丛集性头痛：已在加拿大获得批准

2021-06-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

UCB在《Lancet》上发表bimekizumab治疗斑块状银屑病的全新数据

2021-02-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量

2021-03-18

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM: Trastuzumab Deruxtecan治疗HER2阳性晚期胃癌II期效果显著

2020-12-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JAMA Netw Open：新型减肥药Bimagrumab 对2型糖尿病和肥胖成人体脂质量的影响

2021-04-20

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性

2021-10-18

snf701207 (审核中...)

前往app查看评论内容

#mAb#

CD20单抗Ublituximab与PI3K抑制剂Umbralisib联合治疗慢性淋巴细胞白血病，获FDA快速通道指定

2021-01-17

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌

2021-06-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

美国国立卫生研究院选择Lenzilumab进行COVID-19的大效应试验（BET）

2020-12-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Blood：依鲁替尼、Obinutuzumab和Venotclax联合治疗复发性/初治套细胞淋巴瘤

2021-03-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Heart J：Alirocumab 对高龄冠心病患者预后的影响研究

2020-09-18

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Tocilizumab用于新冠肺炎住院患者的治疗

2020-11-20

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA批准CD38单抗DARZALEX（daratumumab）与卡非佐米和地塞米松联合，治疗复发或难治性多发性骨髓瘤

2021-03-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA授予Zenocutuzumab治疗NRG1基因融合肿瘤的“快速通道资格”

2021-11-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2021-05-05

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JACC：Evolocumab对血脂异常HIV携带者的疗效研究

2020-11-20

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2021-02-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著

2020-09-23

科室
- - 订阅+
  - 更多科室
工具
服务